13.63
price up icon2.10%   0.28
after-market Handel nachbörslich: 13.63
loading

Upstream Bio Inc Aktie (UPB) Neueste Nachrichten

pulisher
Jul 23, 2025

What drives Upstream Bio Inc. stock priceOutstanding trading profits - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Upstream Bio Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Upstream Bio Inc. stockOutstanding capital returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Upstream Bio Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

J.P. Morgan Maintains UpStream Bio(UPB.US) With Buy Rating - 富途牛牛

Jul 19, 2025
pulisher
Jul 18, 2025

how upstream bio inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest

Jul 18, 2025
pulisher
Jul 17, 2025

What risks could impact Upstream Bio Inc. stock performanceHigh Potential Shares - Newser

Jul 17, 2025
pulisher
Jul 15, 2025

Why Upstream Bio Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Upstream Bio Inc. stock performs during market volatilityFast Gains With Reduced Risk - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Upstream Bio management to meet with Piper Sandler - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Upstream Bio Inc. stock price move sharplyFree VIP Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Will Q3 Shape Up To Be A VIBRANT Quarter For Upstream Bio? - RTTNews

Jul 09, 2025
pulisher
Jul 08, 2025

Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio announces first patient dosed in phase 2 clinical trial of Verekitug - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio begins phase 2 COPD trial for verekitug - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio Announces First Patient Dosed in Phase 2 - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough COPD Drug Trial Launches with Unique 24-Week Dosing Schedule, Targeting 670 Patients - Stock Titan

Jul 08, 2025
pulisher
Jun 30, 2025

Upstream Bio, Inc.(NasdaqGS: UPB) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 27, 2025
pulisher
Jun 19, 2025

Upstream Bio Plunges 11.54% Amid Clinical Trial Data Anticipation - AInvest

Jun 19, 2025
pulisher
Jun 16, 2025

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks

Jun 16, 2025
pulisher
Jun 15, 2025

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable

Jun 15, 2025
pulisher
Jun 15, 2025

Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times

Jun 15, 2025
pulisher
Jun 15, 2025

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail

Jun 11, 2025
pulisher
Jun 08, 2025

Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Upstream Bio to Present Mechanistic Insights into - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Upstream Bio to Reveal Latest Inflammatory Disease Treatment Progress at Major Goldman Sachs Conference - Stock Titan

Jun 04, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):